- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
Regeneron Pharmaceuticals Sees Institutional Investor Shift
Hunter Perkins Capital Management reduces stake in biotech firm
Mar. 29, 2026 at 10:50am
Got story updates? Submit your updates here. ›
Hunter Perkins Capital Management LLC, an institutional investor, lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% during the fourth quarter, according to a recent SEC filing. The firm now owns 10,887 shares of the biopharmaceutical company's stock, valued at $8,403,000.
Why it matters
Regeneron Pharmaceuticals is a major player in the biotech industry, known for its innovative drug discovery technologies. Shifts in institutional ownership can provide insights into market sentiment and investor confidence around the company's future prospects.
The details
According to the filing, Hunter Perkins Capital Management sold 729 shares of Regeneron Pharmaceuticals during the fourth quarter. The firm's total holdings in the company now represent approximately 1.9% of its investment portfolio, making it the 13th largest position. Other institutional investors have also modified their positions in Regeneron, with some increasing and others decreasing their stakes.
- The filing covers the fourth quarter of 2025.
- The shares were sold on an unspecified date during that quarter.
The players
Hunter Perkins Capital Management LLC
An institutional investment management firm that has reduced its stake in Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals, Inc.
A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.
The takeaway
The reduction in Hunter Perkins Capital Management's position in Regeneron Pharmaceuticals is a sign that some institutional investors may be reevaluating their exposure to the biotech sector. However, Regeneron remains a significant holding for the firm, and the company's innovative drug pipeline and technologies continue to attract investor interest.
